PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30366785-10	2020	ACP and TET (100 mug/ml) treatment significantly inhibited the mRNA expression of iNOS, COX-2, TNF-alpha in LPS treated RAW 264.7 cells.	tetrandrine	8-11	cytochrome c oxidase II, mitochondrial	Mus musculus	88-93	
27457881-4	2016	Tetrandrine increased MSC PGE2 secretion through the NF-kappaB/COX-2 signaling pathway.	tetrandrine	0-11	cytochrome c oxidase II, mitochondrial	Mus musculus	63-68	
24722146-0	2014	Antinociceptive effect of tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKbeta phosphorylation and the COX-2/PGE2 pathway in mice.	tetrandrine	26-37	cytochrome c oxidase II, mitochondrial	Mus musculus	120-125	
24722146-10	2014	Our results suggest that TET can effectively exert antinociceptive effects on LPS-induced hyperalgesia in mice by inhibiting IKKbeta phosphorylation, which leads to the reduction in the production of important pain mediators, such as PGE2 and COX-2, via the IKKbeta/IkappaB/NF-kappaB pathway.	tetrandrine	25-28	cytochrome c oxidase II, mitochondrial	Mus musculus	243-248	
34247115-9	2021	Further, RT-PCR showed that the ectopic transcription of inflammation-associated genes including TNFalpha, IL-1beta, IL-6, COX-2, iNOS, and p65 was reversed in 5XFAD mice treated with tetrandrine.	tetrandrine	184-195	cytochrome c oxidase II, mitochondrial	Mus musculus	123-128	
34247115-11	2021	Tetrandrine pre-treatment also inhibited the expression of TLR4, p65, iNOS, and COX-2 in BV2 cells induced by Abeta 1-42.	tetrandrine	0-11	cytochrome c oxidase II, mitochondrial	Mus musculus	80-85